A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

NCT03893682 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped Change in corporate strategy

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Non-Hodgkin's Lymphoma

Interventions

DRUG: CG-806

Sponsor

Aptose Biosciences Inc.